Human paraoxonase 1 hydrolysis of nanomolar chlorpyrifos-oxon concentrations is unaffected by phenotype or Q192R genotype

Toxicology Letters

Volumn 230, Issue 1, 2014, Pages 57-61

  Coombes, R Hunter ^a,c   Meek, Edward C ^a   Dail, Mary Beth ^a   Chambers, Howard W ^b   Chambers, Janice E ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Chlorpyrifos oxon; Paraoxonase 1; Polymorphism; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS; CHOLINESTERASE INHIBITOR; DIAZOXON; NANOMOLARCHLORPYRIFOS OXON; PARAOXON; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME METABOLISM; FEMALE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOTE; HUMAN; HYDROLYSIS; LIMIT OF DETECTION; MALE; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROPHOTOMETRY; TOXICOGENETICS; VELOCITY;

CHLORPYRIFOS-OXON; PARAOXONASE 1; POLYMORPHISM; PON1;

ARYLDIALKYLPHOSPHATASE; CHLORPYRIFOS; HOMOZYGOTE; HUMANS; HYDROLYSIS; INSECTICIDES; KINETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SPECTROPHOTOMETRY;

EID: 84906519026     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.07.029     Document Type: Article

References (29)

1. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 1993, 52:598-608.
2. Aldridge W.N., Davison A.N. The mechanism of inhibition of cholinesterases by organophosphorus compounds. Biochem. J. 1953, 55:763-766.
3. Chambers H.W., Brown B., Chambers J.E. Non-catalytic detoxication of six organophosphorus compounds by rat liver homogenates. Pestic. Biochem. Physiol. 1990, 36:308-315. 10.1016/004-3575(90)90040-9.
4. Chambers J.E., Chambers H.W. An investigation of acetylcholinesterase inhibition and aging and choline acetyltransferase activity following a high level acute exposure to paraoxon. Pestic. Biochem. Physiol. 1989, 33:125-131. 10.1016/0048-3575(89)90003-5.
5. Chambers J.E., Ma T., Boone J.S., Chambers H.W. Role of detoxication pathways in acute toxicity levels of phosphorothionate insecticides in the rat. Life Sci. 1994, 54:1357-1364. 10.1016/0024-3205(94)515-X.
6. Cole T.B., Jampsa R.L., Walter B.J., Arndt T.L., Richter R.J., Shih D.M., Twart A., Lusis A.J., Jack R.M., Costa L.G., Furlong C.E. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 2003, 13:357-364. 10.1016/0024-3205(94)515-X.
7. Cole T.B., Walter B.J., Shih D.M., Tward A.D., Lusis A.J., Timchalk C., Richer R.J., Costa L.G., Furlong C.E. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet. Genom. 2005, 15:589-598. 10.1097/01.fpc.0000167327.08034.d2.
8. Coombes R.H., Crow J.A., Dail M.B., Chambers H.W., Wills R.W., Bertolet B.D., Chambers J.E. Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Pharmacogenet. Genom. 2011, 21:867-875. 10.1097/FPC.6013e32834cebc6.
9. Costa L.G., McDonald B.E., Murphy S.D., Omenn G.S., Richter R.J., Motulsky A.G., Furlong C.E. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol. 1990, 103:66-76. 10.1016/0041-008X(90)90263-T.
10. Costa L.G. Toxic effects of pesticides. Casarett and Doull's Toxicology: The Basic Science of Poisons 2008, 883-930. McGraw Hill Medical Inc., New York. C.D. Klaassen (Ed.).
11. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 1996, 14:334-336. 10.1038/ng1196-334.
12. Eckerson H.W., Romson J., Wyte C., La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am. J. Hum. Genet. 1983, 35:214-227.
13. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95. 10.1016/0006-2952(61)90145-9.
14. Furlong C.E., Richter R.J., Seidel S., Costa L.G., Motulsky A. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal. Biochem. 1989, 180:242-247. 10.1016/0003-2697(89)90424-7.
15. Furlong C.E. Paraoxonases: an historical perspective. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism 2008, 3-32. Springer, The Netherlands. B. Mackness, M. Mackness, M. Aviram, G. Paragh (Eds.).
16. Gaines T.B. Acute toxicity of pesticides. Toxicol. Appl. Pharmacol. 1969, 14:515-534. 10.1016/0041-008X(69)90013-1.
17. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 1993, 3:73-76. 10.1038/ng0193-73.
18. Jansen K.L., Cole T.B., Park S.S., Furlong C.E., Costa L.G. Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol. Appl. Pharmacol. 2009, 236:142-153. 10.1016/jtaap.2009.02.001.
19. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 2000, 20:516-521. 10.1161/01.ATV.20.2.516.
20. Li W.F., Furlong C.E., Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 1995, 76:219-226. 10.1016/0378-4274(95)80006-Y.
21. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779. 10.1097/00008571-200012000-00002.
22. Neal R.A. Studies of the enzymatic mechanism of the metabolism of diethyl 4-nitrophenyl phosphorothionate (parathion) by rat liver microsomes. Biochem. J. 1967, 105:289-297.
23. Poh R., Muniandy S. Evaluation of polymorphism at codon 192 of paraoxonase 1 on its kinetic behavior. J. Biol. Sci. 2009, 9:541-548. 10.3923/jbs.2009.541.548.
24. Pond A.L., Coyne C.P., Chambers H.W., Chambers J.E. Identification and isolation of two rat serum proteins with A-esterase activity toward paraoxon and chlorpyrifos-oxon. Biochem. Pharmacol. 1996, 52:363-369. 10.1016/0006-2952(96)215-8.
25. Shih D.M., Gu L., Xia Y.R., Nawab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287. 10.1038/28406.
26. Sogorb M.A., García-Argüelles S., Carrera V., Vilanova E. Serum albumin is as efficient as paraoxonase in the detoxification of paraoxon at toxicologically relevant concentrations. Chem. Res. Toxicol. 2008, 21:1524-1529. 10.1021/tx800075x.
27. Sogorb M.A., Vilanova E. Serum albumins and detoxification of anti-cholinesterase agents. Chem. Biol. Interact. 2010, 187:325-329. 10.1016/j.cbi.2010.03.001.
28. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2214-2225. 10.1161/01.ATV.19.9.2214.
29. Stevens R.C., Suzuki S.M., Cole T.B., Park S.S., Richter R.J., Furlong C.E. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Nat. Acad. Sci. U. S. A. 2008, 105:12780-12784. 10.1073/pnas.0805865105.